Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia Amylyx (Nasdaq: AMLX) announced completion of enrollment in the pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia, with the last participant randomized and dosed and a total of 78 participants enrolled.The 16-week double-blind trial evaluates the FDA-agreed primary outcome of reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16. Topline data are anticipated in Q3 2026, with commercial launch targeted in 2027 if approved; NDA-readiness preparations are underway.

#AMLX Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

www.stocktitan.net/news/AMLX/amylyx-pharmac...

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results Amylyx Pharmaceuticals (Nasdaq: AMLX) reported Q4 and full-year 2025 results and clinical updates on March 3, 2026. Key points: LUCIDITY recruitment is complete for the Phase 3 avexitide trial with topline data expected in Q3 2026, cash, cash equivalents and short-term investments of $317.0M at 12/31/2025, and a cash runway expected into 2028. Full-year net loss narrowed to $144.7M ($1.53/sh). The company advanced preclinical candidate AMX0318 and reported early Phase 1 AMX0114 tolerability data.

#AMLX Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/AMLX/amylyx-pharmac...

Most Searched, Tuesday January 6, 2026 – Crystal Equity Research

Most searched small-cap stocks, Tue Jan 6th - #SLS #JBLU #RR #LAC #AZI #NVTS #ALMS #PLUG #USAR #RDW #RCAT #NAK #METC #LODE #KMT #DVLT #CRML #BYND #ASST #AMLX - More: crystalequityresearch.com/most-searche... - #smallcap

Amylyx Pharmaceuticals Reports Positive Early Safety Data for AMX0114 in ALS LUMINA Trial Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced early safety and tolerability results from the first cohort of its Phase 1 LUMINA trial evaluating AMX0114

Amylyx Pharmaceuticals (NASDAQ: #AMLX) reports early Phase 1 LUMINA trial data: AMX0114 is well-tolerated in ALS patients with no treatment-related serious adverse events. Enrollment for cohort 2 to begin soon.
prismmarketview.com/amylyx-pharm...

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial Amylyx Pharmaceuticals (NASDAQ: AMLX) presented early Phase 1 LUMINA safety and tolerability data for AMX0114 at the 36th International Symposium on ALS/MND on December 5-7, 2025. In cohort 1 (n=12), AMX0114 was generally well-tolerated with no treatment-related serious adverse events, and no dose-limiting toxicities were observed to date.Based on these data, Amylyx plans to open enrollment for cohort 2 in Canada later in December 2025 and in the U.S. in January 2026. Biomarker data from cohort 1 are expected in the first half of 2026. Presentations include safety/tolerability and preclinical biomarker characterization sessions at the MNDA symposium.

#AMLX Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

www.stocktitan.net/news/AMLX/amylyx-pharmac...

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? | The Motley Fool One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

#AMLX #a0b05c59-25d4-4747-a275-c5f4fb754214 #coveragefilings

Origin | Interest | Match

Most Searched, Wednesday November 19, 2025 – Crystal Equity Research

Most searched small-cap stocks, Wed Nov 19th - #LAC #KZIA #RXRX #QUBT #SGML #SGML #SEMR #EOSE #NUVB #OLMA #DNN #AGIO #PLUG #SGBX #ONDS #IQ #EVH #CEP #CAAS #BORR #AMLX - More: crystalequityresearch.com/most-searche... - #smallcap

Clinical Trial Setback: Amylyx's AMX0035 Shows No Benefit in Progressive Supranuclear Palsy Study Amylyx ends ORION program after AMX0035 shows no difference vs placebo in PSP treatment at 24 weeks. Company shifts focus to Phase 3 LUCIDITY trial and Wolfram syndrome development.

#AMLX Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

www.stocktitan.net/news/AMLX/amylyx-pharmac...

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results Amylyx Pharmaceuticals (NASDAQ: AMLX) reported Q2 2025 financial results and clinical pipeline updates. The company maintains a strong cash position of $180.8 million as of June 30, 2025, with runway through 2026. Key highlights include expected completion of recruitment for the Phase 3 LUCIDITY trial of avexitide in PBH in 2025, with topline data anticipated in H1 2026.The company reported positive data from multiple clinical programs: Phase 2b trial of avexitide showed 64% reduction in hypoglycemic events, Week 48 data from HELIOS trial of AMX0035 in Wolfram syndrome demonstrated sustained improvements, and AMX0114 received FDA Fast Track designation for ALS treatment. Q2 2025 financial results showed a net loss of $41.4 million ($0.46 per share), improved from $72.7 million loss in Q2 2024.

#AMLX Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/AMLX/amylyx-pharmac...

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 Amylyx Pharmaceuticals (NASDAQ: AMLX) presented new exploratory analyses from Phase 2 and Phase 2b trials of avexitide, a first-in-class GLP-1 receptor antagonist, at ENDO 2025. The drug, which has FDA Breakthrough Therapy designation, showed promising results for post-bariatric hypoglycemia (PBH) treatment.Key findings include a 64% reduction in Level 2 and Level 3 hypoglycemic events with avexitide 90 mg once daily, with over half of participants experiencing no events during treatment. Pharmacokinetic data confirmed sustained therapeutic exposure for 24 hours. The pivotal Phase 3 LUCIDITY trial is currently ongoing, with recruitment completion expected in 2025 and topline data in first half of 2026.

#AMLX Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

www.stocktitan.net/news/AMLX/amylyx-pharmac...

#AMLX #1d8b13a1-a5cb-46ca-8d76-e7785043cbb7 #investing

Origin | Interest | Match

Amylyx Secures Critical FDA Fast Track for Revolutionary ALS Drug as Phase 1 Trial Progresses Novel ALS treatment targeting calpain-2 receives FDA fast-track status. Early data from LUMINA trial expected this year. Learn about this breakthrough approach.

#AMLX Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

www.stocktitan.net/news/AMLX/amylyx-pharmac...

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome Amylyx Pharmaceuticals (NASDAQ: AMLX) has reported positive 48-week results from its Phase 2 HELIOS clinical trial of AMX0035 in treating Wolfram syndrome. The trial demonstrated sustained improvements or stabilization across multiple disease measures, including pancreatic function, glycemic control, and vision.Key findings at Week 48 include a mean increase of +34.5 min*ng/mL in C-peptide response, improved glycemic control with HbA1c reduction of -0.40%, and increased time in target glucose range by +9.6%. The treatment was generally well-tolerated, with only mild to moderate adverse events and no serious treatment-related issues. All participants reported stability or improvement in their symptoms according to both patient and clinician assessments.The company plans to use these results and FDA discussions to design a Phase 3 trial. AMX0035 has received Orphan Drug Designation from both FDA and European Commission for Wolfram syndrome treatment.

#AMLX Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

www.stocktitan.net/news/AMLX/amylyx-pharmac...

Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results Amylyx Pharmaceuticals reported Q1 2025 financial results and pipeline updates. The company is advancing its Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia, with enrollment completion expected in 2025 and topline data in H1 2026. Key financial metrics include cash position of $204.1 million as of March 31, 2025, with runway through 2026, and Q1 net loss of $35.9 million ($0.42/share). R&D expenses decreased to $22.1M from $36.6M YoY, while SG&A expenses dropped to $15.7M from $57.8M. The company recently raised $65.5M through a public offering and began dosing in the Phase 1 LUMINA trial for ALS. Upcoming milestones include Week 48 data from HELIOS trial in Wolfram syndrome and Phase 2b ORION trial results in Q3 2025.

#AMLX Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/AMLX/amylyx-pharmac...

Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia Amylyx Pharmaceuticals has initiated its pivotal Phase 3 LUCIDITY trial for avexitide, dosing its first participant. The trial aims to evaluate this first-in-class GLP-1 receptor antagonist for treating post-bariatric hypoglycemia (PBH). The study will involve approximately 75 participants across 20 U.S. sites, with completion expected in 2025 and topline data in first half of 2026. The FDA-approved trial will assess avexitide's ability to reduce hypoglycemic events in patients who underwent Roux-en-Y gastric bypass surgery. Key highlights: Avexitide holds FDA Breakthrough Therapy and Orphan Drug Designations Previous five clinical trials showed consistent, positive results Participants will receive either 90 mg avexitide or placebo daily 16-week treatment period followed by 32-week open-label extension Company maintains cash runway through end of 2026

#AMLX Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia

www.stocktitan.net/news/AMLX/amylyx-pharmac...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks in new uptrend with average directional index, Wed Apr 23rd - #AREN #OKYO #GAUZ #VBTX #SIGA #RLMD #PESI #NEON #SNOA #JANX #IRIX #FHTX #EDIT #DRCT #CNCK #AMLX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Breakthrough ALS Treatment Enters Human Trials: Amylyx Targets New Disease Mechanism Novel antisense therapy AMX0114 begins Phase 1 testing in ALS patients. Targeting calpain-2 protein, this innovative approach shows promise in preclinical studies.

#AMLX Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis

www.stocktitan.net/news/AMLX/amylyx-pharmac...

Can Amylyx Recover? Q4 Results Show $301.7M Loss But Pipeline Progress and Extended Cash Runway Despite significant 2024 losses, Amylyx secured additional funding and reduced expenses while advancing Phase 3 LUCIDITY trial with results expected in H1 2026.

#AMLX Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/AMLX/amylyx-pharmac...

FDA Lifts Clinical Hold on Amylyx's New ALS Drug Trial, AMX0114 Set for 2025 Launch Amylyx Pharmaceuticals advances AMX0114, its novel ALS treatment, as FDA clears Phase 1 LUMINA trial. Study to evaluate safety across 48 patients in US and Canada.

#AMLX Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

www.stocktitan.net/news/AMLX/amylyx-pharmac...

JUST IN: ( NASDAQ: #AMLX ) Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation

Amylyx Pharmaceuticals Announces $60M Public Offering at $3.50 Per Share to Fund Growth Amylyx seeks to raise $60M through 17.1M share offering, bolstering commercialization efforts and pipeline development. Leerink Partners leads the underwriting.

#AMLX Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

www.stocktitan.net/news/AMLX/amylyx-pharmac...

Amylyx Pharmaceuticals Announces Common Stock Offering to Fuel Commercialization Plans Amylyx launches public offering with 15% additional share option, partnering with Leerink Partners. Proceeds to support commercialization efforts and pipeline development.

#AMLX Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/AMLX/amylyx-pharmac...

Just In: ( NASDAQ: #AMLX ) Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

#StockMarket #News

Just In: ( NASDAQ: #AMLX ) Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference

#StockMarket #News

#AMLX Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference

www.stocktitan.net/news/AMLX/amylyx-pharmac...

Just In: ( NASDAQ: #AMLX ) Why Amylyx Pharmaceuticals Stock Was So Healthy This Week

#StockMarket #News

Breaking News: ( NASDAQ: #AMLX ) Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

#StockMarket #News

News; ( NASDAQ: #AMLX ) Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024

#StockMarket #News

Just In: ( NASDAQ: #AMLX ) Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration

#StockMarket #News

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#SOUN, #NOK, #AMLX, #ST, #DKNG

#OptionFlow #OptionsTrading #Trading